About: Anti-SARS-CoV-2 Potential of Artemisinins In Vitro

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti-SARS-CoV-2 Potential of Artemisinins In Vitro Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Anti-SARS-CoV-2 Potential of Artemisinins In Vitro
Creator	Liu, Jia Li, Wei Zhong, Wu Wang, Xi Zhao, Lei Li, Yufeng Hu, Zhihong Wang, Manli Xu, Mingyue Zhang, Tianhong Cao, Ruiyuan Hu, Hengrui Zhang, Huanyu Yang, Jingjing Guo, Xiaojia Li, Yuexiang Xiao, Dian Yan, Yunzheng
source	Medline; PMC
abstract	[Image: see text] The discovery of novel drug candidates with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) potential is critical for the control of the global COVID-19 pandemic. Artemisinin, an old antimalarial drug derived from Chinese herbs, has saved millions of lives. Artemisinins are a cluster of artemisinin-related drugs developed for the treatment of malaria and have been reported to have multiple pharmacological activities, including anticancer, antiviral, and immune modulation. Considering the reported broad-spectrum antiviral potential of artemisinins, researchers are interested in whether they could be used to combat COVID-19. We systematically evaluated the anti-SARS-CoV-2 activities of nine artemisinin-related compounds in vitro and carried out a time-of-drug-addition assay to explore their antiviral mode of action. Finally, a pharmacokinetic prediction model was established to predict the therapeutic potential of selected compounds against COVID-19. Arteannuin B showed the highest anti-SARS-CoV-2 potential with an EC(50) of 10.28 ± 1.12 μM. Artesunate and dihydroartemisinin showed similar EC(50) values of 12.98 ± 5.30 μM and 13.31 ± 1.24 μM, respectively, which could be clinically achieved in plasma after intravenous administration. Interestingly, although an EC(50) of 23.17 ± 3.22 μM was not prominent among the tested compounds, lumefantrine showed therapeutic promise due to high plasma and lung drug concentrations after multiple dosing. Further mode of action analysis revealed that arteannuin B and lumefantrine acted at the post-entry step of SARS-CoV-2 infection. This research highlights the anti-SARS-CoV-2 potential of artemisinins and provides leading candidates for anti-SARS-CoV-2 drug research and development.
has issue date	2020-07-31(xsd:dateTime)
bibo:doi	10.1021/acsinfecdis.0c00522
bibo:pmid	32786284
has license	no-cc
sha1sum (hex)	068d17182e2fda3e2e3245372bc8a391e5c29eb6
schema:url	https://doi.org/10.1021/acsinfecdis.0c00522
resource representing a document's title	Anti-SARS-CoV-2 Potential of Artemisinins In Vitro
has PubMed Central identifier	PMC7437450
has PubMed identifier	32786284
schema:publication	ACS Infect Dis
resource representing a document's body	covid:068d17182e2fda3e2e3245372bc8a391e5c29eb6#body_text
is schema:about of	named entity 'antiviral' named entity 'intravenous administration' named entity 'promise' named entity 'discovery' named entity 'carried' named entity 'potential' named entity 'COVID-19' named entity 'drugs' named entity 'drug' named entity 'COVID-19' named entity 'artemether' named entity 'Physiologically Based Pharmacokinetic' named entity 'PI3-K/Akt' named entity 'pharmacokinetic' named entity 'kidney' named entity 'Cytotoxicity' named entity 'viral protein' named entity 'Petri dishes' named entity 'Western blotting' named entity 'artesunate' named entity 'one-way analysis of variance' named entity '0.01' named entity 'protein' named entity 'artemisinins' named entity 'lumefantrine' named entity 'Alexa 488' named entity 'HBV' named entity 'viral RNA' named entity 'Chloroquine' named entity 'artemisinins' named entity 'SARS-CoV-2' named entity 'NIH' named entity 'dye' named entity 'HCMV' named entity 'bovine serum albumin' named entity 'PBS' named entity 'hepatic' named entity 'lungs' named entity 'infection' named entity 'lopinavir/ritonavir' named entity 'antimalarial drug' named entity 'antiviral' named entity 'secondary antibody' named entity 'HIV protease inhibitors' named entity 'PBPK' named entity 'coartem' named entity 'dihydroartemisinin' named entity 'Immunofluorescence Assay' named entity 'synergistic' named entity 'Vero E6' named entity 'lumefantrine' named entity 'lumefantrine' named entity 'clinical trials' named entity 'SARS-CoV-2' named entity 'serum' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'lumefantrine' named entity 'half-life' named entity 'inoculum' named entity 'PBPK' named entity 'supernatant' named entity 'lung' named entity 'artemisinins'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software